PIK3CG and cancer: Initial studies in cancer genomics relying on single platform analyses (mostly gene expression- and protein-based) have discovered multiple candidate “druggable” targets such as KRAS mutation in colon and lung cancer [1], BRAF in colorectal, thyroid, and melanoma cancers [2], and PI3K in breast, colon and ovarian cancers [3].